# US 2017/0304323 A1 · Controlled release and taste masking oral pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0304323 A1
- Document ID: US20170304323A1
- Status: Published application
- Kind: A1
- Application number: 15/646,538
- Filed: 2017-07-11
- Published: 2017-10-26
- Earliest claimed: 1999-06-14
- Assignees: Cosmo Technologies Limited
- Applicants: Cosmo Technologies Limited
- Inventors: Roberto VILLA; Massimo PEDRANI; Mauro AJANI; Lorenzo FOSSATI
- Web page: https://patentgrep.com/patent/US20170304323A1

## CPC

- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/2806: {Coating materials}
- A61K 9/2813: {Inorganic compounds}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 11/08: Bronchodilators
- A61P 11/14: Antitussive agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.

## Claims

### Claim 1

A controlled release oral pharmaceutical composition consisting essentially of:
(1) a tablet core comprising:
a) budesonide in an amount to treat intestinal inflammation;
b) magnesium stearate, stearic acid, or a mixture thereof;
c) hydroxyalkyl cellulose; and
d) optionally starch or a starch derivative; and
(2) a coating on said tablet core, said coating consisting essentially of a gastro-resistant film.

### Claim 2 (depends on 1)

The controlled release oral pharmaceutical composition according to claim 1, wherein said tablet core comprises magnesium stearate.

### Claim 3 (depends on 1)

The controlled release oral pharmaceutical composition according to claim 1, wherein said tablet core comprises stearic acid.

### Claim 4 (depends on 1)

The controlled release oral pharmaceutical composition according to claim 1, wherein said tablet core comprises starch.

### Claim 5 (depends on 4)

The controlled release oral pharmaceutical composition according to claim 4, wherein said tablet core comprises magnesium stearate.

### Claim 6 (depends on 4)

The controlled release oral pharmaceutical composition according to claim 4, wherein said tablet core comprises stearic acid.

### Claim 7 (depends on 1)

The controlled release oral pharmaceutical composition according to claim 1, wherein said tablet core comprises a starch derivative.

### Claim 8 (depends on 7)

The controlled release oral pharmaceutical composition according to claim 7, wherein said tablet core comprises magnesium stearate.

### Claim 9 (depends on 7)

The controlled release oral pharmaceutical composition according to claim 7, wherein said tablet core comprises stearic acid.

### Claim 10 (depends on 1)

The controlled release oral pharmaceutical composition according to claim 1, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 11 (depends on 2)

The controlled release oral pharmaceutical composition according to claim 2, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 12 (depends on 3)

The controlled release oral pharmaceutical composition according to claim 3, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 13 (depends on 4)

The controlled release oral pharmaceutical composition according to claim 4, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 14 (depends on 5)

The controlled release oral pharmaceutical composition according to claim 5, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 15 (depends on 6)

The controlled release oral pharmaceutical composition according to claim 6, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 16 (depends on 7)

The controlled release oral pharmaceutical composition according to claim 7, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 17 (depends on 8)

The controlled release oral pharmaceutical composition according to claim 8, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 18 (depends on 9)

The controlled release oral pharmaceutical composition according to claim 9, wherein said gastro-resistant film comprises methacrylic acid polymer.

### Claim 19 (depends on 1)

A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to claim 1.

### Claim 20 (depends on 2)

A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to claim 2.

### Claim 21 (depends on 3)

A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to claim 3.
